{
  "timestamp": "2026-02-11T06:50:00.000Z",
  "scorer": "opus-4.6-interactive",
  "source_recording": "record-2026-02-11-0627.json",
  "cycle": 8,
  "cycle_description": "SOURCE UTILIZATION prompt (FAILED) + c-TRAK TN seed",
  "fixes_applied": [
    "Added SOURCE UTILIZATION prompt section (REVERTED — caused regression)",
    "Seeded c-TRAK TN trial (PMID 36423745, ID 382) for TNBC MRD-guided evidence",
    "Deployed to Railway with updated server.js"
  ],
  "summary": {
    "averageScore": 7.8,
    "maxScore": 10,
    "passRate": "5/10",
    "passPercentage": 50,
    "failing": 5,
    "errors": 0,
    "notes": "MAJOR REGRESSION. SOURCE UTILIZATION prompt caused widespread degradation. Q7 citation-validator leaked system instructions into response. Q9 C3 false positive on 'versus stopping therapy'. IDEA/DYNAMIC still not cited by Sonnet despite being in RAG. c-TRAK TN not surfacing for Q4 yet. Prompt reverted, citation leak and C3 lookbehind fixed in follow-up commit."
  },
  "dimensionAverages": {
    "accuracy": 1.6,
    "completeness": 1.2,
    "evidence_quality": 1.3,
    "automation_bias_mitigation": 1.0,
    "criterion3_nondirective": 1.8,
    "criterion4_transparency": 1.0
  },
  "comparison_to_c7": {
    "passRate": "10/10 → 5/10 (REGRESSION)",
    "avgScore": "9.0 → 7.8 (down 1.2!)",
    "improvements": [],
    "regressions": [
      "Q2: 8→7 (DYNAMIC/IDEA still missing)",
      "Q3: 9→7 (DYNAMIC missing, T4a mischaracterized)",
      "Q4: 8→6 (pembrolizumab/KEYNOTE-522/c-TRAK TN all missing)",
      "Q7: 9→7 (citation-validator system instructions leaked into response)",
      "Q9: 10→6 (C3 forbidden language 'versus stopping therapy' + completeness gaps)",
      "Q10: 8→7 (IMvigor011 identified but positive results not reported)"
    ],
    "stable": ["Q1(9), Q5(9), Q6(10), Q8(10)"]
  },
  "score_progression": {
    "original": { "passRate": "80%", "avg": 8.6 },
    "c1b": { "passRate": "90%", "avg": 8.7 },
    "c2": { "passRate": "90%", "avg": 8.7 },
    "c3": { "passRate": "100%", "avg": 8.9 },
    "c4": { "passRate": "90%", "avg": 8.8 },
    "c5": { "passRate": "90%", "avg": 8.6 },
    "c6": { "passRate": "100%", "avg": 9.1 },
    "c7": { "passRate": "100%", "avg": 9.0 },
    "c8": { "passRate": "50%", "avg": 7.8, "note": "REVERTED — prompt regression" }
  },
  "results": [
    {
      "id": 1,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "Stable. DYNAMIC mentioned briefly. NCCN/ESMO correctly cited. Missing CIRCULATE and NRG-GI005 specifics."
    },
    {
      "id": 2,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "total": 7,
      "pass": false,
      "summary": "DYNAMIC and IDEA both missing despite being #1 and #6 in RAG results. Sonnet ignores them in generation. GALAXY cited but observational. Critical omission for 3-vs-6-month question."
    },
    {
      "id": 3,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "total": 7,
      "pass": false,
      "summary": "DYNAMIC missing for stage II CRC question. T4a mischaracterized as not meeting criteria for adjuvant chemo. GALAXY cited with HRs. Regressed from C7."
    },
    {
      "id": 4,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 0,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 3
      },
      "total": 6,
      "pass": false,
      "summary": "Worst score of any question. Missing pembrolizumab/KEYNOTE-522, olaparib, c-TRAK TN. Generic 'clinical trial enrollment' without naming any specific agents or trials. c-TRAK TN was seeded but didn't surface."
    },
    {
      "id": 5,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 1,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 6
      },
      "total": 9,
      "pass": true,
      "summary": "Strong. TREAT ctDNA, SERENA-6, c-TRAK TN (cross-indication) all cited. Missing specific median lead time figure."
    },
    {
      "id": 6,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 7
      },
      "total": 10,
      "pass": true,
      "summary": "Outstanding. ADAURA OS benefit correctly framed. MERMAID-1 exclusion criteria noted. Consistent 10/10."
    },
    {
      "id": 7,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "total": 7,
      "pass": false,
      "summary": "BUG: Citation-validator system instructions ('SENTENCES NEEDING CITATIONS OR REWORDING', 'AVAILABLE SOURCES', 'RULES') leaked into clinician-facing output. GALAXY data adequate but presentation broken. Fixed in follow-up commit."
    },
    {
      "id": 8,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 2,
        "completeness": 2,
        "evidence_quality": 2,
        "automation_bias_mitigation": 1,
        "subtotal": 7
      },
      "total": 10,
      "pass": true,
      "summary": "HPV ctDNA distinction maintained. NavDx performance data accurate. Cross-indication well-flagged. Consistent 10/10."
    },
    {
      "id": 9,
      "category": "clinical_scenario",
      "difficulty": "challenging",
      "automated": { "criterion3": 0, "criterion4": 1, "subtotal": 1 },
      "llm": {
        "accuracy": 2,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 5
      },
      "total": 6,
      "pass": false,
      "summary": "C3 FAIL: 'versus stopping therapy' triggered forbidden pattern. Missing MSI status/immunotherapy discussion. Fixed lookbehind in follow-up commit."
    },
    {
      "id": 10,
      "category": "clinical_scenario",
      "difficulty": "standard",
      "automated": { "criterion3": 2, "criterion4": 1, "subtotal": 3 },
      "llm": {
        "accuracy": 1,
        "completeness": 1,
        "evidence_quality": 1,
        "automation_bias_mitigation": 1,
        "subtotal": 4
      },
      "total": 7,
      "pass": false,
      "summary": "IMvigor011 identified and PMID correct, but did NOT report positive results (DFS HR 0.64, OS HR 0.59). For a clinician asking about the readout, omitting that it was a positive trial is a critical gap."
    }
  ]
}
